CHICAGO, Ill., July 11, 2016 — As he completed his term as president of the Society for Vascular Surgery (SVS), Dr. Bruce A. Perler began his term as chair of the SVS Foundation at the society’s 2016 Vascular Annual Meeting near Washington, D.C. in June.
Dr. Michel S. Makaroun, a professor of surgery and of clinical and translational science at the University of Pittsburgh, was elected vice president of the Society for Vascular Surgery (SVS) at the Society’s 2016 Vascular Annual Meeting in June.
R. Clement Darling III, MD, was elected president-elect of the Society for Vascular Surgery (SVS) at the 2016 Vascular Annual Meeting in June.
[[{"type":"media","view_mode":"media_large","fid":"840","attributes":{"alt":"","class":"media-image","height":"480","style":"width: 177px; height: 198px; float: left; margin-left: 8px; margin-right: 8px;","typeof":"foaf:Image","width":"430"}}]]CHICAGO, Ill., July 11, 2016 — Vascular surgeon
CHICAGO, Illinois - Conventional wisdom might suppose that everyone would avoid surgery if possible.
CHICAGO, Illinois, May 6, 2016 –The Society for Vascular Surgery Board of Directors is pleased to announce Kenneth M. Slaw, Ph.D., as the society’s next executive director, replacing Rebecca Maron, CAE, who will retire May 30, 2016.
Chicago, Illinois– Could microbes in the gut impact human arteries? Surprising early research suggests they might play a role.
CHICAGO, Illinois - Previous studies have shown that women are more likely than men to die after vascular surgery, but a new study shows that they are far more likely to be readmitted to the hospital after aortic aneurysm surgery as well.
A recent review of patients who had undergone carotid, lower extremity bypass, or abdominal aortic aneurysm surgeries found that patients who received both statins and antiplatelet medications were far more likely to be alive five years later. Patients placed on both an antiplatelet agent and cholesterol medication had an adjusted 40 percent reduced risk of death at five years compared to those who received neither drug. Being on either one of these medications was also important, and was associated with an adjusted 30 percent reduced risk of death compared to those on neither medication. When considered differently, an extra 14 of every 100 patients were alive at five years if on both medications.